JillWieserMD

Dermatology • Maple Grove, MN

Board-Certified Dermatologist

Join to view full profile

Dr. Wieser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wieser's full profile

Already have an account?

Office
7840 Vinewood Ln N
Maple Grove, MN 55369

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Dermatology, 2021 - 2024
University of RochesterFellowship, Dermatology, 2019 - 2021
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 2018 - 2019
University of North Dakota School of Medicine and Health SciencesClass of 2018

Certifications & Licensure

MN State Medical License 2024 - 2025
OH State Medical License 2021 - 2024
NY State Medical License 2019 - 2021
American Board of Dermatology Dermatology

Clinical Trials

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Start of enrollment: 2015 Oct 15
Active, not recruiting
Phase 3
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis Start of enrollment: 2018 Jul 25
Terminated
Phase 4
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Mar 08
Active, not recruiting
Phase 3
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects Start of enrollment: 2018 Jun 11
Completed
Phase 3
ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis Start of enrollment: 2019 Feb 20
Completed
Phase 3
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. Start of enrollment: 2018 Dec 28
Completed
Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Start of enrollment: 2019 Mar 11
Completed
Phase 2
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 3
Study of Skin Microbiome in AD and PS Patients Start of enrollment: 2019 Apr 17
Recruiting
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) Start of enrollment: 2019 Dec 11
Active, not recruiting
Phase 3
A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD) Start of enrollment: 2020 Feb 17
Terminated
Phase 1
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Start of enrollment: 2020 Nov 12
Terminated
Phase 2
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring Start of enrollment: 2020 Feb 13
Completed
Not Applicable
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients Start of enrollment: 2021 Feb 15
Recruiting
Join now to see all

Publications & Presentations

PubMed

9 citations
Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment.
Jill K. Wieser, Gina J. Kuehn, James C Prezzano, Elizabeth H. Cusick, Julia Stiegler
JAAD Case Reports. 2020-03-25
6 citations
Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series.
Jill K. Wieser, Mary Gail Mercurio, Kathryn Somers
Cureus. 2020-06-21
28 citations
Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US.
Andrew Creadore, Sheena Desai, Allireza Alloo, Anna K Dewan, Mina Bakhtiar
JAMA Dermatology. 2022-02-01

Journal Articles

From flare to care: Dermatologists' impact on pediatric atopic dermatitis hospital admissions
Jill K. Wieser MD, Benjamin I. Larson MPH, Sonal D. Shah MD, Pediatric Dermatology, 7/25/2024
Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis
Julie Ryan Wolf, Anita Chen, Jill Wieser, Brad Johnson, Lauren Baughman, Gayin Lee, Eleanor Pope, Abigail Franco, Tanzy Love, Lisa A. Beck, Journal of the European Academy of Dermatology & Venereology, 2/15/2024

Lectures

Pembrolizumab-related eruptive keratoacanthomas
Cleveland, OH - 9/29/2022
Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon
Cleveland, OH - 9/9/2021

Other

Multibacillary leprosy with histopathologic absence of globi and evolving cutaneous morphology
Mandy Alhajj, DO, Scott Mahlberg, DO, Idy Tam, MD, Jill Wieser, MD, Adrienne Callahan, MD, Kord Honda, MD, poster presentation
American Society of Dermatopathology Annual Meeting - 10/2023
American Academy of Dermatology Question of the Week - acquired perforating dermatosis
Jill Wieser, MD; Bethany Rohr, MD, online
https://learning.aad.org/Users/Question.aspx
question number 26/52 - 6/29/2023
New England Journal of Medicine Healer - Hidradenitis Suppurativa illness script
Wieser J; Vidmar D; and Nedorost, S, online
https://healer.nejm-qa.org/ed/
2023
New England Journal of Medicine Healer - rash schemas
Nedorost S; Vidmar D; Malerich P; Barlev D; Jonas M; Alhajj M; Johnson A; Liou Y; Mahlberg S; Scarberry K; Wieser J, online
https://healer.nejm-qa.org/ed/
2023
Tinea Manus
Jill K Wieser MD, Susan Burgin MD, VisualDx
https://www.visualdx.com/visualdx/diagnosis/tinea+manus?diagnosisId=52401&moduleId=102
10/11/2019
Join now to see all